Oclacitinib-13C-d3 is a deuterated form of oclacitinib, a selective Janus kinase (JAK) inhibitor primarily used in veterinary medicine for the treatment of allergic dermatitis in dogs. The incorporation of deuterium (13C-d3) into the molecular structure enhances its stability and can improve pharmacokinetic properties, making it useful for research purposes, particularly in metabolic studies and drug development. Oclacitinib works by inhibiting the JAK pathway, which plays a crucial role in the signaling of various cytokines involved in inflammatory processes. This selective inhibition helps to reduce inflammation and pruritus without broadly suppressing the immune system. The compound is typically administered orally and is characterized by its relatively rapid absorption and metabolism. As a research chemical, Oclacitinib-13C-d3 is valuable for studying the drug's behavior in biological systems, including its distribution, metabolism, and excretion. Safety and efficacy profiles are well-documented in veterinary applications, but specific characteristics of the deuterated form may vary based on its isotopic labeling.

Oclacitinib-13C-d3 is intended for use as an internal standard for the quantification of oclacitinib (Item No. 18722) by GC- or LC-MS. Oclacitinib is an inhibitor of the JAK family kinases JAK1, JAK2, JAK3, and TYK2 (IC50s = 10, 18, 99, and 84 nM, respectively).1 It is selective for JAK kinases over a panel of 38 additional kinases at 1 μM. Oclacitinib inhibits LPS-induced increases in IL-12 and TNF-α levels in murine bone marrow-derived dendritic cells (BMDCs) in a concentration-dependent manner.2 Topical administration of oclacitinib (0.1, 0.25, and 0.5%) reduces scratching behavior and ear edema, as well as decreases levels of IL-1β, IL-4, and IL-6 in ear skin, in a mouse model of allergic dermatitis induced by toluene-2,3-diisocyanate (TDI). Formulations containing oclacitinib have been used in the treatment of pruritus associated with allergic dermatitis and the control of atopic dermatitis in dogs.WARNING This product is not for human or veterinary use.

Oclacitinib-13C-d3

2750534-84-8: Oclacitinib-13C-d3 is a deuterated form of oclacitinib, a selective Janus kinase (JAK) inhibitor primarily used in veterinary medicine for the treatment of allergic dermatitis in dogs. The incorporation of deuterium (13C-d3) into the molecular structure enhances its stability and can improve pharmacokinetic properties, making it useful for research purposes, particularly in metabolic studies and drug development. Oclacitinib works by inhibiting the JAK pathway, which plays a crucial role in the signaling of various cytokines involved in inflammatory processes. This selective inhibition helps to reduce inflammation and pruritus without broadly suppressing the immune system. The compound is typically administered orally and is characterized by its relatively rapid absorption and metabolism. As a research chemical, Oclacitinib-13C-d3 is valuable for studying the drug's behavior in biological systems, including its distribution, metabolism, and excretion. Safety and efficacy profiles are well-documented in veterinary applications, but specific characteristics of the deuterated form may vary based on its isotopic labeling.

CAS 2750534-84-8

Oclacitinib-13C-d3

Oclacitinib-13C-d3

Ref: 4Z-O-059002